Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationCost of RevenueEBIATLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Receivables - NetReceivables - OtherShares Repurchased
Ratios

Collegium Pharmaceutical (COLL) Accumulated Depreciation & Amortization (2016 - 2025)

Collegium Pharmaceutical has reported Accumulated Depreciation & Amortization over the past 10 years, most recently at $16.5 million for Q4 2025.

  • Quarterly results put Accumulated Depreciation & Amortization at $16.5 million for Q4 2025, up 22.23% from a year ago — trailing twelve months through Dec 2025 was $16.5 million (up 22.23% YoY), and the annual figure for FY2025 was $16.5 million, up 22.23%.
  • Accumulated Depreciation & Amortization for Q4 2025 was $16.5 million at Collegium Pharmaceutical, up from $13.5 million in the prior quarter.
  • Over the last five years, Accumulated Depreciation & Amortization for COLL hit a ceiling of $16.5 million in Q4 2025 and a floor of $4.7 million in Q4 2021.
  • Median Accumulated Depreciation & Amortization over the past 5 years was $9.7 million (2023), compared with a mean of $10.2 million.
  • Biggest five-year swings in Accumulated Depreciation & Amortization: surged 53.66% in 2021 and later increased 22.23% in 2025.
  • Collegium Pharmaceutical's Accumulated Depreciation & Amortization stood at $4.7 million in 2021, then skyrocketed by 34.65% to $6.3 million in 2022, then skyrocketed by 53.06% to $9.7 million in 2023, then soared by 39.84% to $13.5 million in 2024, then increased by 22.23% to $16.5 million in 2025.
  • The last three reported values for Accumulated Depreciation & Amortization were $16.5 million (Q4 2025), $13.5 million (Q4 2024), and $9.7 million (Q4 2023) per Business Quant data.